alex

Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).

The Center for Commercialization of Cancer Immunotherapy (C3i) and the Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-EMTL) are proud to announce the participation of Gilead Sciences Canada, Inc. in supporting the development of a Lymphoma Registry.

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce a partnership with Hôpital Maisonneuve-Rosemont (HMR) and Dr. Isabelle Fleury, Hematologist and Medical Oncologist at HMR, to support the development of a Lymphoma Registry.

Miami, FA – January 22nd-25th 2017

Montreal, QC – December 13th-15th 2017

Atlanta, GA – December 9th-12th 2017

C3i will attend the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam from December 5th to 7th to engage with researchers, clinicians and industry leaders in… Read More »

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.

November 14th-16th, 2017

The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i

$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products